Aptima® Trichomonas vaginalis assay

The most common curable STI

Trichomonas vaginalis (TV) is the most common curable STI in the United states.1 Over 3.7 million people in the United States have TV, which is a higher prevalence than chlamydia and gonorrhea infections combined.1 The CDC recommends testing women for TV infection if they are symptomatic or at increased risk of infection.2 The CDC and ACOG also recommend the use of a highly sensitive and specific test, such as the Aptima® Trichomonas vaginalis assay.2,3
 

Detect up to 100% of TV Infections

The Aptima Trichomonas vaginalis assay is an rRNA-based NAAT that provides up to 100% sensitivity in detecting TV for both symptomatic and asymptomatic patients.4 This assay overcomes challenges associated with traditional, less sensitive methodologies because it can detect a fraction of one organism, whereas wet mount requires at least 10,000 motile organisms/mL to visualize.4,5


References: 1. CDC. CDC Fact Sheet: Incidence, Prevalence and Cost of Sexually Transmitted Infections in the United States. https://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf. February 2013. 2. Workowski, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70(4):1-187.doi.org/10.15585/mmwr.rr7004a1. 3. ACOG Practice Bulletin. Vaginitis in Nonpregnant Patients. Washington; DC: American College of Obstetricians and Gynecologists; 2020:135:e1-17. No. 215. 4. Aptima Trichomonas vaginalis Assay. US package insert 503684. Hologic, Inc., 2020. 5. Garber GE. The laboratory diagnosis of Trichomonas vaginalis. Can J Infect Dis Med Microbiol. 2005; 16(1):35-38. doi.org/10.1155/2005/373920
 

Information provided on this tab is intended for audiences outside the United States. Consult "USA" tab for products and claims available in the United States
 

The most common curable STI

Trichomonas vaginalis (TV) is the most prevalent nonviral STI in the world with a global incidence of 156 million.1,2 TV has a higher prevalence for women than chlamydia and gonorrhea infections combined.2 If left untreated, TV is associated with consequences such as cervicitis, preterm birth, and concurrent STIs.1,3 Proper diagnosis is important to drive treatment decisions and prevent transmission, so it is recommended to use a highly sensitive and specific test such as the CE-marked Aptima Trichomonas vaginalis assay.1,4
 

Detect up to 100% of TV Infections

The Aptima Trichomonas vaginalis assay is an rRNA-based NAAT that provides up to 100% sensitivity in detecting TV for both symptomatic and asymptomatic patients.5 This assay overcomes challenges associated with traditional, less sensitive methodologies because it can detect a fraction of one organism, whereas wet mount requires at least 10,000 motile organisms/mL to visualize.5,6


References: 1. Workowski, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70. 2. Rowley, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates 2016. Bull World Health Organ 2019;97:548–562. doi: 10.2471/BLT.18.228486. 3. Shew ML, et al. Association of condom use, sexual behaviors and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006;160(2):151-156. doi:10.1001/archpedi.160.2.151. 4. ACOG. Vaginitis in Nonpregnant Patients. ACOG Practice Bulletin. Number 215. 2020;135(1):e1-e17. 5. Aptima Trichomonas vaginalis assay. UK package insert. 502536EN-IFU-PI. Hologic, Inc., 2019. 6. Garber GE. The laboratory diagnosis of Trichomonas vaginalis. Can J Infect Dis Med Microbiol. 2005;16(1):35-38.
 
Want Image Slider on Tab Click
no